• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Preparation and optimization of surface stabilized cryptotanshinone nanocrystals with enhanced bioavailability
In conclusion, the results of this study suggest a feasible formulation for the oral delivery of CTS.
Source: Frontiers in Pharmacology - February 3, 2023 Category: Drugs & Pharmacology Source Type: research

Exploring the potential mechanism of Fritiliariae Irrhosae Bulbus on ischemic stroke based on network pharmacology and experimental validation
Conclusion: Based on network pharmacology, the effect of FIB in the treatment of ischemic strokes was discussed through the multi-component-multi-target-multi-pathway. The therapeutic effect and potential mechanisms of FIB on ischemic strokes were preliminarily explored, which provided a ground work for further researches on the pharmacodynamic material basis, mechanism of action and clinical application.
Source: Frontiers in Pharmacology - November 17, 2022 Category: Drugs & Pharmacology Source Type: research

Mini-Review on SARS-CoV-2 Infection and Neurological Manifestations: A Perspective
CNS Neurol Disord Drug Targets. 2021 Jul 6. doi: 10.2174/1871527320666210706103422. Online ahead of print.ABSTRACTThe coronavirus, also known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus-19), with its rapid rate of transmission, has progressed with a great impact on respiratory function and mortality worldwide. The nasal cavity is the promising gateway of SARS-CoV-2 to reach the brain via systemic circulatory distribution. Recent reports have revealed that the loss of involuntary process of breathing control into the brainstem that results in death is a signal of neurological involvement. Early neurologica...
Source: CNS and Neurological Disorders Drug Targets - December 30, 2021 Category: Drugs & Pharmacology Authors: Vishal Chavda Arif Tasleem Jan Dhananjay Yadav Source Type: research

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Hepatitis C virus (HCV) infection is a systemic disease associated with multiple significant extrahepatic manifestations. Emerging studies indicate association between the HCV infection and a higher incidence of major adverse cardiovascular events such as: coronary artery disease, heart failure, stroke and peripheral artery disease, when compared to general population. Atherosclerosis is a common pathophysiologic mechanism of cardiovascular disease (CVD) development which is the leading cause of mortality in the Western world. Proposed mechanisms of HCV-induced atherosclerosis includes systemic inflammation due to the chro...
Source: Frontiers in Pharmacology - May 11, 2021 Category: Drugs & Pharmacology Source Type: research

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France
ConclusionExtrahepatic manifestations of HCV infection substantially add to the overall economic burden of the disease in France. HCV cure after anti‐viral therapy is expected to significantly reduce the total costs of managing these manifestations in France.
Source: Alimentary Pharmacology and Therapeutics - October 18, 2017 Category: Drugs & Pharmacology Authors: P. Cacoub, M. Vautier, A. C. Desbois, D. Saadoun, Z. Younossi Tags: ORIGINAL ARTICLE Source Type: research

Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
CONCLUSION: A 63-year-old man on a stable dose of warfarin experienced a decrease in INR values after the initiation of a 12-week course of sofosbuvir and ribavirin for the treatment of chronic HCV infection. PMID: 28596225 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - June 11, 2017 Category: Drugs & Pharmacology Authors: Peterson D, Van Ermen A Tags: Am J Health Syst Pharm Source Type: research

Interferon‐based therapy reduces risk of stroke in chronic hepatitis C patients: a population‐based cohort study in Taiwan
ConclusionsInterferon‐based therapy may reduce the long‐term risk of stroke in patients with chronic HCV infection.
Source: Alimentary Pharmacology and Therapeutics - June 29, 2013 Category: Drugs & Pharmacology Authors: C.‐S. Hsu, J.‐H. Kao, Y.‐C. Chao, H. H. Lin, Y.‐C. Fan, C.‐J. Huang, P.‐S. Tsai Tags: Original Article Source Type: research

Associations of chronic hepatitis C with metabolic and cardiac outcomes
ConclusionsChronic hepatitis C virus infection is independently associated with presence of metabolic conditions (insulin resistance, type 2 diabetes and hypertension) and congestive heart failure.
Source: Alimentary Pharmacology and Therapeutics - February 5, 2013 Category: Drugs & Pharmacology Authors: Z. M. Younossi, M. Stepanova, F. Nader, Z. Younossi, E. Elsheikh Tags: Original Article Source Type: research